Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $74.06 USD
Change Today -0.20 / -0.27%
Volume 557.9K
ALKS On Other Exchanges
As of 8:10 PM 11/25/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

Connaught House

1 Burlington Road

Dublin, 4


Phone: 353 1 772 8000


YDUREON expire in 2029, 2023 and 2025 in the U.S., respectively; and 2021, 2021 and 2024 in Europe, respectively. The company also has patent protection for its key development programs. U.S. Patent No. 8,431,576 and U.S. Patent No. 8,796,276, which issued in April 2013 and August 2014, respectively, cover a class of compounds that includes aripiprazole lauroxil and expire no earlier than 2030. U.S. Patent No. 7,262,298, which covers a class of compounds that includes the opioid modulators in each of the ALKS 5461 and ALKS 3831 combination products, expires in 2025. U.S. Patent No. 8,822,488, which issued in September 2014, covers ALKS 5461 and would expire no earlier than 2032. U.S. Patent No. 8,680,112, which issued in March 2014, contains method of treatment claims that would cover ALKS 5461, ALKS 3831 and ALKS 7106 and would expire in 2029. U.S. Patent No. 8,778,960, which issued in July 2014, covers ALKS 3831 and would expire no earlier than 2032. U.S. Patent No. 8,802,655, which issued in August 2014, covers ALKS 7106 and would expire no earlier than 2025. U.S. Patent No. 8,669,281, which issued in March 2014, contains composition of matter claims that would cover ALKS 8700 and would expire in 2033. The company is involved in various Paragraph IV litigations in the U.S. and other proceedings outside of the U.S. involving its patents in respect of TRICOR, MEGACE ES, AMPYRA, and ZOHYDRO ER. The company’s trademarks, including VIVITROL, are important to the company and are generally covered by trademark applications or registrations in the U.S. Patent and Trademark Office and the patent or trademark offices of other countries. The company’s partnered products also use trademarks that are owned by its partners, such as the marks RISPERDAL CONSTA and INVEGA SUSTENNA, which are registered trademarks of Johnson & Johnson Corp.; BYDUREON, which is a trademark of Amylin; and AMPYRA and FAMPYRA, which are registered trademarks of Acorda. Regulation The company makes its products available for purchase by authorized users of the Federal Supply Schedule (FSS) of the General Services Administration pursuant to the company’s FSS contract with the Department of Veterans Affairs. Under the Veterans Health Care Act of 1992, the company is required to offer discounted FSS contract pricing to four federal agencies, such as the Department of Veterans Affairs; the Department of Defense; the Coast Guard; and the Public Health Services (including the Indian Health Service), for federal funding to be made available for reimbursement of any of its products by such federal agencies and certain federal grantees. The company is subject to the U.S. Foreign Corrupt Practices Act, which prohibits the U.S. corporations and their representatives from paying, offering to pay, promising, authorizing, or making payments of anything of value to any foreign government official, government staff member, political party, or political candidate in an attempt to obtain or retain business or to otherwise influence a person working in an official capacity. The company is also subject to the UK Bribery Act, which proscribes giving and receiving bribes in the public and private sectors, bribing a foreign public official and failing to have adequate procedures to prevent employees and other agents from giving bribes. The company is subject to various financial disclosure and securities trading regulations as a public company in the U.S., including laws relating to the oversight activities of the Securities and Exchange Commission and the regulations of the NASDAQ Global Select Stock Market, on which its shares are traded. Competition In the treatment of schizophrenia, RISPERDAL CONSTA and INVEGA SUSTENNA compete with various other injectable products, including ZYPREXA RELPREVV ((olanzapine) For Extended Release Injectable Suspension), which is marketed and sold by Eli Lilly & Company; and ABILIFY MAINTENA (aripiprazole for extended release injectable suspension), a once-monthly injectable formulation of ABILIFY (aripiprazole) developed by Otsuka Pharmaceutical Co., Ltd. In the treatment of alcohol dependence, VIVITROL compete


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALKS:US $74.06 USD -0.20

ALKS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioMarin Pharmaceutical Inc $96.06 USD -1.74
Impax Laboratories Inc $44.72 USD +0.64
Incyte Corp $115.41 USD +3.69
Jazz Pharmaceuticals PLC $150.45 USD +3.43
Lupin Ltd 1,836 INR -24.75
View Industry Companies

Industry Analysis


Industry Average

Valuation ALKS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 17.3x
Price/Book 8.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 15.6x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact ALKERMES PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at